期刊
NEURON
卷 104, 期 4, 页码 637-653出版社
CELL PRESS
DOI: 10.1016/j.neuron.2019.09.018
关键词
-
资金
- Wellcome [202747/Z/16/Z]
- Wellcome Pain Consortium [102645]
- European Commission Horizon 2020 [ID633491]
- Novo Nordisk Foundation [NNF14SA0006]
- NIH NIDA [P50 DA039841]
- NINDS [NS105880, NS105880-01S1, 1U01HG010230-01]
- Fondecyt Regular [1161019]
- NHMRC [APP1111940, APP1158164, APP1158165, APP1107514]
- NSW Ministry of Health
- Neuropathic pain and Genetics Special Interest Groups of IASP
- Wellcome Trust [202747/Z/16/Z] Funding Source: Wellcome Trust
- BBSRC [BB/S006788/1] Funding Source: UKRI
Neuropathic pain (NeuP) arises due to injury of the somatosensory nervous system and is both common and disabling, rendering an urgent need for non-addictive, effective new therapies. Given the high evolutionary conservation of pain, investigative approaches from Drosophila mutagenesis to human Mendelian genetics have aided our understanding of the maladaptive plasticity underlying NeuP. Successes include the identification of ion channel variants causing hyper-excitability and the importance of neuro-immune signaling. Recent developments encompass improved sensory phenotyping in animal models and patients, brain imaging, and electrophysiology-based pain biomarkers, the collection of large well-phenotyped population cohorts,neurons derived from patient stem cells, and high-precision CRISPR generated genetic editing. We will discuss how to harness these resources to understand the pathophysiological drivers of NeuP, define its relationship with comorbidities such as anxiety, depression, and sleep disorders, and explore how to apply these findings to the prediction, diagnosis, and treatment of NeuP in the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据